mFlusiva Approval — First mRNA Flu Vaccine Cleared by the FDA
The FDA approved Moderna's mFlusiva on Aug 5, 2026 — the first mRNA seasonal flu vaccine — for adults 50 and older, after trials showed about 27% better protection than standard flu shots.
A milestone for the mRNA platform
Four and a half years after mRNA COVID-19 vaccines proved the platform at scale, the FDA's August 5 approval of mFlusiva extended the technology to seasonal influenza for the first time. The pivotal data showed roughly 27% better protection against influenza-like illness than standard-dose comparators in adults 50 and older.[1][2][3]
The clearance also carried political weight: it arrived after an unusual regulatory detour in which the application was initially refused review, making the eventual approval a signal moment for mRNA products in a contentious policy environment. Moderna plans a US rollout for the 2026-27 season and is pursuing approvals in Europe, Canada, and Australia.[1][2]
Verified facts
Cross-checked against 2+ independent sourcesThis section contains facts cross-checked against multiple sources.
On August 5, 2026, the FDA approved Moderna's mFlusiva (formerly mRNA-1010), the first US-approved seasonal influenza vaccine built on mRNA technology.[1][2][3] 3 sources
The vaccine is approved for adults aged 50 and older.[1][2] 2 sources
In clinical trials, mFlusiva reduced the likelihood of influenza-like illness by about 27% relative to standard-dose flu vaccines in adults 50 and older, with results published in the New England Journal of Medicine.[2][3] 2 sources
Moderna expects mFlusiva to be available in the US for the 2026-2027 flu season, with regulatory submissions underway in Europe, Canada, and Australia.[1][2] 2 sources
Reported, not confirmed
Not cross-checked — do not read as factFrom here on: claims and speculation that are not cross-checked.
For adults 65 and older, the approval was granted under an accelerated pathway that requires a postmarketing confirmatory study spanning two flu seasons.[2] single-source ×1 · Healthcare Dive reporting on the FDA action
The approval followed a reversal at the FDA: previous agency leadership initially refused to review the application citing data gaps, then changed course after public backlash and a formal meeting with Moderna, with interim leadership later taking a more favorable stance.[2] single-source ×1 · Healthcare Dive account of the regulatory history
Moderna CEO Stephane Bancel said the vaccine 'provides an important new option for America's seniors' and reflects 'the ongoing potential of our mRNA platform.'[2] single-source ×1 · Moderna statement
No new serious safety concerns emerged in trials; typical adverse reactions included fatigue, joint pain, and muscle aches.[2] single-source ×1 · trial safety data as reported by Healthcare Dive
Timeline
Outcome
- Model
- claude-opus-5
- Time
- 08/23/2026, 01:30
- Tokens
- 8,000
- Sources
- 3 sources adopted
- Model
- claude-opus-5 (review pass)
- Time
- 08/23/2026, 01:30
- Tokens
- 3,000
- Verdict
- Passed
| 08/23/2026, 01:30 | First authored (claude-opus-5) | Created |
| 08/23/2026 | First authored | Updated |
Frequently asked
How is mFlusiva different from existing flu shots?
Conventional flu vaccines are mostly grown in eggs or cell culture months in advance; an mRNA vaccine can be designed and manufactured faster, potentially allowing a closer strain match. In trials it was about 27% more effective than standard-dose shots at preventing influenza-like illness in adults 50+.
Who can get it and when?
The approval covers adults 50 and older, and Moderna expects availability in the US for the 2026-2027 flu season.
Why was the approval considered a turnaround?
The application had earlier been refused review amid a skeptical posture toward mRNA products at the agency; after criticism and further engagement with Moderna, the FDA reviewed and approved the vaccine.
Official links
- Official FDA — Press announcements